Enovis Corp (ENOV)
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.
- Symbol
- ENOV
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $1.05B
- 52 week range
- 17.3 - 34.28
Valuation
- Share price
- $18.24 (close of 2026-09-23)
- P/E (TTM)
- -0.95x
- Price to book
- 0.71x
- Price to free cash flow
- 16.52x
- Enterprise value
- $2.41B
- Book value per share
- $25.65
Price performance
| Period | Change |
|---|
| 1 day | +1.11% |
| 5 days | +1.67% |
| 1 month | -30.01% |
| 3 months | -13.76% |
| 6 months | -18.97% |
| Year to date | -31.53% |
| 1 year | -41.46% |
| 3 years | -64.69% |
| 5 years | -76.96% |
| 10 years | -63.99% |
| All time | -49.53% |
Profitability and growth
- Return on equity
- -79.39%
- Return on invested capital
- -39.65%
- Return on assets
- -30.89%
- Return on capital employed
- -34.74%
- Gross margin
- 59.84%
- Net margin
- -52.69%
- EBITDA margin
- 9.78%
- Revenue growth
- 6.66%
- Net income growth
- -43.48%
- Free cash flow growth
- 129.63%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.05%
- Current ratio
- 1.98x
- Net debt to EBITDA
- -1.84x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $2.25B
- Cost of revenue
- $902.79M
- Gross profit
- $1.35B
- EBITDA
- $219.89M
- Net income
- $-1.18B
- Research and development
- $120.33M
- Interest expense
- $34.82M
Income statement by year
| Period end | Revenue | Gross profit | Net income |
|---|
| 2025-12-31 | $2.25B | $1.35B | $-1.18B |
| 2024-12-31 | $2.11B | $1.18B | $-825.49M |
| 2023-12-31 | $1.71B | $990.78M | $-33.26M |
| 2022-12-31 | $1.56B | $869.38M | $-13.29M |
| 2021-12-31 | $1.43B | $777.67M | $71.66M |
| 2020-12-31 | $1.12B | $603.64M | $42.63M |
| 2019-12-31 | $3.33B | $1.40B | $-527.65M |
| 2018-12-31 | $2.19B | $729.38M | $140.20M |
| 2017-12-31 | $1.94B | $671.58M | $151.09M |
| 2016-12-31 | $3.19B | $992.38M | $128.11M |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 59.84% | -52.69% | -79.39% | -39.65% |
| 2024-12-31 | 56.02% | -39.17% | -32.19% | -19.79% |
| 2023-12-31 | 58.04% | -1.95% | -0.97% | -1.34% |
| 2022-12-31 | 55.62% | -0.85% | -0.39% | -1.89% |
| 2021-12-31 | 54.53% | 5.02% | 1.54% | -0.71% |
| 2020-12-31 | 53.86% | 3.80% | 1.19% | -0.57% |
| 2019-12-31 | 42.11% | -15.86% | -15.12% | 3.00% |
| 2018-12-31 | 33.26% | 6.39% | 4.03% | 3.30% |
| 2017-12-31 | 34.67% | 7.80% | 4.05% | 3.04% |
| 2016-12-31 | 31.15% | 4.02% | 4.14% | 4.43% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $36.39M | $1.26B |
| 2024-12-31 | $48.17M | $1.31B |
| 2023-12-31 | $36.19M | $466.16M |
| 2022-12-31 | $24.30M | $40.00M |
| 2021-12-31 | $680.25M | $2.08B |
| 2020-12-31 | $97.07M | $2.20B |
| 2019-12-31 | $109.63M | $2.28B |
| 2018-12-31 | $77.15M | $1.19B |
| 2017-12-31 | $411.63M | $1.06B |
| 2016-12-31 | $208.81M | $1.29B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $19.92M | $32.92M |
| 2024-12-31 | $-67.21M | $29.66M |
| 2023-12-31 | $12.77M | $34.06M |
| 2022-12-31 | $-161.31M | $38.95M |
| 2021-12-31 | $251.86M | $35.35M |
| 2020-12-31 | $187.15M | $28.91M |
| 2019-12-31 | $5.55M | $21.96M |
| 2018-12-31 | $156.72M | $25.10M |
| 2017-12-31 | $150.00M | $21.55M |
| 2016-12-31 | $183.72M | $19.02M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $0.64
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.79 |
| 2026-05-07 | - | - |
| 2026-02-26 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-26 | - | - |
| 2025-02-20 | - | - |
Filings and sources
- Company website
- enovis.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades